2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

4:30PM-6:00PM: Abstract Number: 2885

Expansion of Activated PD-1+ ICOS+ T Follicular and Peripheral Helper Cells in Primary Sjögren’s Syndrome Associates with Abnormalities in B Cell Compartment

5T110 ACR Abstract: Sjögren's Syndrome–Basic & Clinical Science (2880–2885)

4:30PM-6:00PM: Abstract Number: 2858

Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System

5T106 ACR Abstract: Measures of Healthcare Quality I: QI in RA (2856–2861)

4:30PM-6:00PM: Abstract Number: 2881

How Immunological Profile Drives Clinical Phenotype of Primary Sjögren’s Syndrome at Diagnosis: Analysis of 10.500 Patients (Sjögren Big Data Project)

5T110 ACR Abstract: Sjögren's Syndrome–Basic & Clinical Science (2880–2885)

4:30PM-6:00PM: Abstract Number: 2850

Human Toll-like Receptor 8 Adversely Affects Placental Development and Pregnancy Outcomes in a Mouse Model of Systemic Lupus Erythematosus

5T105 ACR Abstract: Innate Immunity (2850–2855)

4:30PM-6:00PM: Abstract Number: 2897

Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy

5T111 ACR Abstract: SLE–Clinical IV: Clinical Outcomes (2892–2897)

4:30PM-6:00PM: Abstract Number: 2864

Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Systemic Juvenile Idiopathic Arthritis

5T107 ACR Abstract: Pediatric Rheum–Clinical II: Treatment Update (2862–2867)

4:30PM-6:00PM: Abstract Number: 2875

Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis

5T109 ACR Abstract: RA–Treatments V: Beyond Individual Compounds (2874–2879)

4:30PM-6:00PM: Abstract Number: 2869

Incorporation of Patient Reported Outcomes Data in the Care of US Veterans with Rheumatoid Arthritis: A Randomized, Controlled Trial

5T108 ACR Abstract: RA–DX, Manifestations, & Outcomes V: Outcomes Measures (2868–2873)

4:30PM-6:00PM: Abstract Number: 2896

Increased Mortality Among Patients with Systemic Lupus Erythematosus after Hydroxychloroquine Discontinuation

5T111 ACR Abstract: SLE–Clinical IV: Clinical Outcomes (2892–2897)

4:30PM-6:00PM: Abstract Number: 2889

Inhibition of Radiographic Progression and Correlation with Changes in Composite Indices of Disease Activity in Patients with Active Psoriatic Arthritis Treated with Intravenous Golimumab, As Measured in a Phase III Trial

5T112 ACR Abstract: Spondyloarthritis Incl PsA–Clinical V: Tx of PsA & Peripheral SpA (2886–2891)

4:30PM-6:00PM: Abstract Number: 2863

Long-Term Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF (crFMF), Hids/Mkd and TRAPS: Results from the Pivotal Phase 3 Cluster Trial

5T107 ACR Abstract: Pediatric Rheum–Clinical II: Treatment Update (2862–2867)

4:30PM-6:00PM: Abstract Number: 2862

Magnitude of Response to TNF Inhibitors in Children with Spondyloarthritis and Sacroiliitis

5T107 ACR Abstract: Pediatric Rheum–Clinical II: Treatment Update (2862–2867)

4:30PM-6:00PM: Abstract Number: 2854

Majeed Syndrome Causing LPIN2 mutations May Prevent Bone “Healing” By Rendering M2 Macrophage Proinflammatory

5T105 ACR Abstract: Innate Immunity (2850–2855)

4:30PM-6:00PM: Abstract Number: 2882

Minimal Progression of Disease Manifestation in Patients with Sjögren’s Syndrome Re-Evaluated Multiple Years after Initial Disease Classification

5T110 ACR Abstract: Sjögren's Syndrome–Basic & Clinical Science (2880–2885)

4:30PM-6:00PM: Abstract Number: 2851

NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis

5T105 ACR Abstract: Innate Immunity (2850–2855)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].